帕利哌酮缓释片治疗精神分裂症的临床效果及安全性  

Efficacy and safety of paliperidone extended - release tablets in the treatment of schizophrenia

作　　者：王群芬 

机构地区：[1]慈溪市第七人民医院精神科,浙江省慈溪315336

出　　处：《中国基层医药》2018年第5期566-569,共4页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省慈溪市科技计划项目（CN2010028）

摘　　要：目的探讨帕利哌酮缓释片治疗精神分裂症的临床效果及安全性。方法选取80例精神分裂症患者为研究对象，遵循单盲随机分配原则分为两组，每组40例，对照组采用利培酮治疗，观察组采用帕利哌酮缓释片治疗，比较两组总有效率、阳性和阴性症状评分（PANSS评分）、精神残疾评分（WHO-DAS11评分）以及不良反应发生率。结果观察组的临床总有效率（95．00％）明显高于对照组（80．00％）（χ^2=4．114，P〈0．05）；治疗后，观察组的PANSS评分、WHO．DASII评分相对于治疗前均明显降低（t=8．002、7．761，均P〈0．05），且其均低于对照组治疗后（t=4．114、3．702，均P〈0．05）；两组不良反应发生率差异无统计学意义（7．50％比10．00％，χ^2==0．157，P〉0．05）。结论采用帕利哌酮缓释片治疗精神分裂症的临床疗效显著，可有效缓解患者的精神障碍，且安全性可靠。Objective To study the clinical effect and safety of paliperidone extended -release tablets in the treatment of schizophrenia. Methods 80 patients with schizophrenia were selected as the research subjects. Accord- ing to randomized single blind, the patients were divided into two groups ,40 cases in each group. The control group was given risperidone treatment, the observation group used paliperidone extended - release tablets treatment. The total effective rate, positive and negative symptoms score （ PANSS score）, mental disability score （ WHO - DAS score II） and the incidence of adverse reactions were compared between the two groups. Results The clinical total effective rate （95.00%） in the observation group was significantly higher than the control group （80.00% , χ^2= = 4.114, P 〈 0.05 ）. After treatment, the PANSS score and WHO - DAS II score in the observation group were significantly decreased compared with before treatment （ t = 8. 002,7. 761, all P 〈 0.05 ）, which were lower than those in the control group after treatment （ t = 4.114,3. 702, all P 〈 0.05 ）. The incidence rate of adverse reaction between the two groups had no statistically significant difference （7.50% vs. 10.00%, χ^2== 0. 157, P 〉 0. 05 ）. Conclusion The clinical efficacy of paliperidone extended - release tablets in the treatment of schizophrenia is significant, which can effectively relieve patients with mental disorders, and it is safe and reliable.

关 键 词：精神分裂症 帕利哌酮缓释片 利培酮 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]